Mark K. Buyyounouski

Author

Also Known As

Buyyounouski, Mark K., M BUYYOUNOUSKI, M Buyyounouski, M K Buyyounouski, M. Buyyounouski, M. K. Buyyounouski, M.K Buyyounouski, M.K. Buyyounouski, Mark Buyyounouski, Mark K Buyyounouski

294

Publications

9.2K

Citations

H-Index

Concepts

All Affiliations

Fox Chase Cancer Center Stanford University The University of Texas MD Anderson Cancer Center University of Michigan Stanford Medicine

About

Mark K. Buyyounouski is an author at Fox Chase Cancer Center specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	59	4.9K
2	Health Sciences	17	21	1.5K
3	Engineering	6	6	174
4	Public Health	2	2	96
5	Education	1	1	31

Mark K. Buyyounouski

102

Publications

8.5K

Citations

H-Index

Page 1

	Year	Citations
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Journal of the National Comprehensive Cancer Network	2020	619
Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer Alan Pollack, Gail Walker, Eric M. Horwitz, Journal of Clinical Oncology	2013	457
RTOG GU Radiation Oncology Specialists Reach Consensus on Pelvic Lymph Node Volumes for High-Risk Prostate Cancer C.A. Lawton, Jeff M. Michalski, Issam El Naqa, International Journal of Radiation OncologyBiologyPhysics UrologySurgical OncologyHigh-risk Prostate CancerMedicineProstatic Disease	2008	404
Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer Jeff M. Michalski, C.A. Lawton, Issam El Naqa, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyRadiation TherapyMedicineBrachytherapyClinical Target Volume	2009	392
Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual Mark K. Buyyounouski, Peter L. Choyke, Jesse K. McKenney, CA A Cancer Journal for Clinicians Prognostic BiomarkersUrologySurgical OncologyGenitourinary CancerMedicine	2017	351
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer Amar U. Kishan, Audrey Dang, Alan J. Katz, JAMA Network Open	2019	302
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022 Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Journal of the National Comprehensive Cancer Network	2022	289
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Journal of the National Comprehensive Cancer Network Urological ResearchSurgical OncologyUrologyUrologic Cancer EpidemiologyGenitourinary Cancer	2017	276
Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancer Stephen A. Boorjian, R. Jeffrey Karnes, Rosalia Viterbo, Cancer	2011	269
A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320 Paul W. Sperduto, Meihua Wang, H. Ian Robins, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyRadiation MedicineRadiation TherapyBrain MetastasesMedicine	2013	268

Page 1